Most physicians said the positives of clozapine's REMS outweighed its negatives. Most also said that mandatory blood testing was necessary, but it created a burden and medication delays. In 2024, an ...

Mavacamten is approved for treating obstructive hypertrophic cardiomyopathy, with real-world data supporting its safety and efficacy. The REMS program is crucial for monitoring mavacamten's safety ...

The FDA’s REMS policy, designed to ensure drug safety, is instead harming individuals with treatment-resistant schizophrenia by imposing burdensome requirements on clozapine, the only FDA-approved ...

Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a clinical pharmacist can optimize mavacamten therapy for patients with obstructive HCM. The ...

The update now reduces the frequency of liver function monitoring to every 3 months from the onset of treatment. The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation ...

In the U.S., schizophrenia remains one of the most severe and debilitating mental health conditions, with effective treatment often out of reach for those who need them most. Clozapine, a medication ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a notification to isotretinoin manufacturers to modify the iPledge Risk Evaluation and ...

A recent study found two-thirds of homeless people have a mental illness, with more than three-quarters of them having experienced it during their lifetimes. Between 10 and 20 percent of the homeless ...